Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Post-bariatric surgery more than 6 months prior to signing the informed consent~* Reported history of Whipple's triad: the occurrence of hypoglycemic symptoms associated with a capillary blood glucose of ≤55 mg/dL, and resolution with glucose or carbohydrate administration.~* Symptomatic hypoglycemia during the baseline/screening oral glucose tolerance test (OGTT), as defined by the presence of plasma glucose ≤55 mg/dL with concomitant autonomic and/or neuroglycopenic symptoms.~Exclusion Criteria:~* Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug.~* Participation in any clinical investigation within 4 weeks prior to dosing~* History of or current insulinoma~* Active infection or significant acute illness within 2 weeks prior to dosing~* Female patients who are pregnant or lactating~* Women of childbearing potential and not utilizing effective contraceptive methods~* Inadequate end organ function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Lyo avexitide 0.05 mg/kg (Type: EXPERIMENTAL): Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
- Part A: Lyo avexitide 0.15 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part A: Lyo avexitide 0.35 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part A: Lyo avexitide 0.46 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part B: Liq avexitide 0.38 (±0.03) mg/kg (Type: EXPERIMENTAL): Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).